Found 7 clinical trials
Effect of Sofosbuvir-daclatasuvir on Angiogenesis
The study aimed at study of the Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection
- 0 views
- 22 Jan, 2021
- 1 location
Re-treatment of HCV Following DAA Failure
HCV infection is treated with oral drugs, termed as 'direct-acting anti-viral agents' (DAAs). In India, four DAAs are available (sofosbuvir [SOF], daclatasvir [DCV], ledipasvir [LDV] and
- 19 views
- 11 Apr, 2021
- 2 locations
Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera
Hepatitis C virus (HCV) infection is associated with significant morbidity and mortality owing to progression of a high percentage (85%) of HCV infected patients to chronic hepatitis, which might lead to the development of liver cirrhosis or hepato cellular carcinoma.. Egypt has possibly the highest HCV prevalence in the world, …
- 0 views
- 24 Mar, 2021
- 1 location
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in treatment-nave participants with chronic HCV infection and early liver disease (F0-F2).
- 0 views
- 02 Mar, 2021
- 3 locations
Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C
Clinical trials evaluating DAA have shown excellent rates of SVR and good safety profiles in patients with CHC infection. Real world data from TARGET, TRIO, IFI, DHCR, DALTON-C, as well as those cohorts from Japan, Taiwan and Korea further confirmed clinical trial findings of DAA in routine practice where populations …
- 0 views
- 19 Jul, 2021
- 10 locations
Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women
This is a prospective, observational, open-label, pharmacokinetic study will evaluate PK of SOF/DAC in lactating HCV-infected females at weaning or women who voluntarily decided to forego breastfeeding to initiate HCV infection treatment. Therefore, drug concentrations can be determined in maternal plasma and milk without risk to the children. HCV infected …
- 0 views
- 01 May, 2021
- 1 location
HCV RAS Testing in Public Health Programs
prevalence of various NS5A RASs, and their effect on outcomes of treatment with daclatasvir-sofosbuvir or sofosbuvir-ledipasvirin patients with chronic HCV. The study aims to assess the prevalence and
- 0 views
- 23 Jan, 2021
- 2 locations